Evidence map›Paper›PMID 19653337›Full record

ArticleWorld journal of gastroenterology2009

Transcriptional down regulation of hTERT and senescence induction in HepG2 cells by chelidonine.

Sakineh Kazemi Noureini, Michael Wink

Open access · hybridAbstract read
In one paragraph

Article in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Alkaloids inFrontiers in pharmacology · 2024
    Review
  4. Journal of microbiology and biotechnology · 2022
    Article
  5. Review
  6. Milky Sap of Greater Celandine (International journal of environmental research and public health · 2020
    Article
  7. Modulatory Effect ofMolecules (Basel, Switzerland) · 2020
    Article
  8. Article
  9. Chelidonine Induces Caspase-Dependent and Caspase-Independent Cell Death through GEvidence-based complementary and alternative medicine : eCAM · 2019
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 3 countries.

Sakineh Kazemi NoureiniDepartment of Biology, Faculty of Basic Sciences, Tarbiat Moallem University of Sabzevar, Sabzevar, Iran. s-kazemi@sttu.ac.ir
Michael Wink
Sabzevar University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the potential effects of chelidonine, the main alkaloid of Chelidonium majus, on telomerase activity and its regulation in HepG2 cells.

methodsCytotoxicity of chelidonine for HepG2 cells was determined by neutral red assay. A modified polymerase chain reaction (PCR)-based telomerase repeat amplification protocol was used to estimate relative telomerase activity in chelidonine-treated cells in comparison with the untreated control cells. Relative expression level of the catalytic subunit of telomerase (hTERT) gene and P-glycoprotein (pgp) were estimated using semi-quantitative real-time reverse transcription-PCR (RT-PCR). Cell senescence in treated cells was demonstrated using a beta-galactosidase test.

resultsCytotoxicity of chelidonine in HepG2 cells was not dose-dependent and tended to reach plateau immediately after the living cells were reduced in number to slightly higher than 50%. However, 12 micromol/L concentration of chelidonine was considered as LD(50), where the maximal attainable effects were realized. Real-time RT-PCR data showed that the expression of pgp increased three-fold in chelidonine treated HepG2 cells in comparison with the untreated controls. Morphologically, treated HepG2 cells showed apoptotic features after 24 h and a small fraction of cells appeared with single blister cell death. The relative expression level of Bcl-2 dropped to less than 50% of control cells at a sub-apoptotic concentration of chelidonine and subsequently increased to higher than 120% at LD(50). Telomerase activity was reduced considerably after administration of very low doses of chelidonine, whereas higher concentrations of chelidonine did not remarkably enhance the effect. Real-time RT-PCR experiments indicated a drastic decrease in expression level of hTERT subunit of telomerase under treatment with chelidonine. Repeated treatment of cells with very low doses of chelidonine caused a decline in growth rate by 4 wk and many of the cells appeared to be aged with large volume and dark staining in the beta-galactosidase assay.

conclusionChelidonine reduces telomerase activity through down-regulation of hTERT expression. Senescence induction might not be directly caused by reducing telomerase activity as it occurs after a few population doublings.

Indexed as

Antineoplastic Agents, PhytogenicApoptosisATP Binding Cassette Transporter, Subfamily B, Member 1Benzophenanthridinesbeta-GalactosidaseCell Line, TumorCellular SenescenceChelidoniumDown-RegulationGenes, bcl-2HumansProto-Oncogene Proteins c-bcl-2TelomeraseAntineoplastic Agents, PhytogenicATP Binding Cassette Transporter, Subfamily B, Member 1Benzophenanthridinesbeta-GalactosidasechelidonineProto-Oncogene Proteins c-bcl-2TelomeraseTERT protein, human

Identifiers

PMID19653337
PMCPMC2721233
OpenAlexW1545076822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.